Neuroblastoma, the most prevalent solid cancer in children, requires more accurate prognostic markers and improved diagnosis survival prediction tools to refine patient stratification due to its diverse clinical behavior and variable treatment response. Thus, innovative approaches could be especially relevant for high-risk patients with poor prognoses to effectively address these complex clinical scenarios.
QP-Insights® emerges as a transformative breakthrough, offering a comprehensive platform for storing and managing patient data, including clinical, molecular, and imaging patient information, while integrating cutting-edge AI algorithms used as clinical decision support systems to enhance patient care and treatment outcomes. In this regard, Quibim has developed a pioneering solution for overall survival prediction in Neuroblastoma patients, leveraging the combination of clinical, molecular, and radiomics data. This solution, was externally validated, showing promising results in patients’ stratification when compared to current clinical standards.
A collaborative effort between top research and academic institutions and Quibim has yielded promising results in pediatric oncology through a European project called PRIMAGE. This project leverages predictive in-silico multiscale analytics to support personalized cancer diagnosis and prognosis, which are empowered by imaging biomarkers. This partnership equips clinicians with advanced tools to aid clinical decision-making, ultimately enhancing outcomes in Neuroblastoma patients. Quibim, in turn, strengthens its position as a pioneer by offering innovative medical imaging solutions that harness the power of integrating multi-omics data in pediatric cancer patients through advanced artificial intelligence methodologies.
Read more
Read more
Read more
